Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy (eBook)
XIII, 260 Seiten
Springer New York (Verlag)
978-1-4614-7070-0 (ISBN)
Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.
?????This volume gives the latest developments in on the mechanisms of cancer cell resistance to apoptotic stimuli, which eventually result in cancer progression and metastasis. One of the main challenges in cancer research is to develop new therapies to combat resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance to cytotoxic drug-induced apoptosis. These mechanisms should reveal gene products that directly regulate resistance in order to develop new drugs that target these resistance factors and such new drugs may either be selective or common to various cancers. If successful, new drugs may not be toxic and may be used effectively in combination with subtoxic conventional drugs to achieve synergy and to reverse tumor cell resistance. The research developments presented in this book can be translated to produce better clinical responses to resistant tumors.
Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.
Part I. Mechanism of tumor cell resistance to cytotoxic apoptosis drugs: Innate versus induced
1. Molecular pathway of apoptosis
2. Molecular anti-apoptotic pathways in cancer
3. Genetic mechanisms that regulate resistance
4. Oncogenesis and tumor cell resistance
5. Molecular heterogeneity of various cancers and cancer stem cells in resistance
6. Molecular signature profiles of resistance in cancers
Part II. Dominant pathways and gene products that regulate resistance
7. Resistant targets for apoptosis
8. Autocrine and Paracrine factors
9. Oncogenes
10.Tumor micro environment
Part III. Selective agents that target resistant mechanisms: Direct and indirect
11. Proteasome inhibitors
12. Chemicals: free and encapsulated in nanoparticles
13. Receptor agonists and antagonists
14. Antibodies
Erscheint lt. Verlag | 4.7.2013 |
---|---|
Reihe/Serie | Resistance to Targeted Anti-Cancer Therapeutics | Resistance to Targeted Anti-Cancer Therapeutics |
Zusatzinfo | XIII, 260 p. |
Verlagsort | New York |
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
Studium ► 2. Studienabschnitt (Klinik) ► Pathologie | |
Naturwissenschaften ► Biologie | |
Technik | |
Schlagworte | ABC Drug transporters • antibacterial drug resistance • Apoptosis • chemoresistance • cytotoxics • HPC1 • β1 Integrins • ß1 Integrins • β1 Integrins |
ISBN-10 | 1-4614-7070-6 / 1461470706 |
ISBN-13 | 978-1-4614-7070-0 / 9781461470700 |
Haben Sie eine Frage zum Produkt? |
Größe: 5,5 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich